Evelina Maines
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Evelina Maines has a total of 290 co-authors. Here are the top co-authors by number of shared publications:
- Roberto Franceschi
Centre for Medical Sciences -CISMed, University of Trento, Trento, Italy
19 shared publications Massimo Soffiati
13 shared publications- Franco Antoniazzi
Department of Surgery, Dentistry, Paediatrics and Gynaecology, University of Verona, 37134 Verona, Italy
9 shared publications Giovanni Piccoli
8 shared publicationsRoberto Franceschi
Ospedale Santa Chiara
8 shared publications- Alberto Burlina
Division of Inherited Metabolic Diseases, University Hospital of Padua, Padua, Italy
6 shared publications
Latest Publications
- Open Access
- 22 September 2026
- Published by Milano University Press in Epidemiology, Biostatistics, and Public Health
Impact of Commercially-Available Hybrid Closed-Loop Systems on Sleep Outcomes in Youths and Adults With Type 1 Diabetes: A Systematic Review and Meta-Analysis
Introduction Closed-loop insulin delivery systems, including hybrid closed-loop (HCL) technologies, are now considered the standard of care for individuals with type 1 diabetes (T1D) and are increasingly adopted by both adults and younger populations. Beyond improving glycemic outcomes, their potential impact on patient-reported outcomes such as sleep has gained increasing attention. However, evidence regarding their effects on sleep quality and duration in individuals with T1D and their caregivers remains inconsistent. Objectives The objective of this study was to assess whether the use of commercially available hybrid closed-loop systems improves subjective sleep quality and objective sleep parameters in youths and adults with type 1 diabetes and in their caregivers compared with standard diabetes management. Methods This systematic review and meta-analysis included randomized and non-randomized studies in children, adolescents, and adults with T1D and their caregivers, evaluating commercially available hybrid closed-loop (HCL) systems. The primary outcome was the PSQI; secondary outcomes included actigraphy-derived parameters (TST, TIB, SE, SOL, NWAK, WASO). Analyses were performed separately by study design and population using a random-effects model (REML; Hartung-Knapp adjustment with IQWiG6 ad hoc correction); risk of bias was assessed with RoB 2 and ROBINS-I, and certainty of evidence with GRADE. Results For the PSQI, RCTs showed no statistically significant effect of HCL in subjects (6 studies, n=573; MD −0.30 [95% CI −0.92; 0.32]) or caregivers (3 studies, n=216; MD −1.39 [95% CI −3.66; 0.88]), despite a trend toward improvement in both groups. Non-randomized pre-post studies, encompassing a larger pooled sample, suggested a statistically significant improvement in sleep quality in both subjects (11 comparisons, n=672; MD −0.40 [95% CI −0.63; −0.17]) and caregivers (7 comparisons, n=372; MD −1.05 [95% CI −1.54; −0.56]). Conclusions Overall, the PSQI findings are directionally favorable to HCL, but the strength of inference differs by study design. The lack of a statistically significant effect in RCTs suggests that any benefit on perceived sleep quality is likely modest and still uncertain. By contrast, non-randomized pre-post studies show a clearer signal, though these results should be interpreted cautiously given their vulnerability to confounding, selection bias, and regression to the mean. The caregiver effect appears more pronounced than the subject effect, possibly reflecting a reduction in nocturnal diabetes-related burden, but this remains hypothesis-generating rather than definitive.
- 22 September 2026
- Published by Milano University Press in Epidemiology, Biostatistics, and Public Health
Open AccessImpact of Commercially-Available Hybrid Closed-Loop Systems on Sleep Outcomes in Youths and Adults With Type 1 Diabetes: A Systematic Review and Meta-Analysis
Introduction Closed-loop insulin delivery systems, including hybrid closed-loop (HCL) technologies, are now considered the standard of care for individuals with type 1 diabetes (T1D) and are increasingly adopted by both adults and younger populations. Beyond improving glycemic outcomes, their potential impact on patient-reported outcomes such as sleep has gained increasing attention. However, evidence regarding their effects on sleep quality and duration in individuals with T1D and their caregivers remains inconsistent. Objectives The objective of this study was to assess whether the use of commercially available hybrid closed-loop systems improves subjective sleep quality and objective sleep parameters in youths and adults with type 1 diabetes and in their caregivers compared with standard diabetes management. Methods This systematic review and meta-analysis included randomized and non-randomized studies in children, adolescents, and adults with T1D and their caregivers, evaluating commercially available hybrid closed-loop (HCL) systems. The primary outcome was the PSQI; secondary outcomes included actigraphy-derived parameters (TST, TIB, SE, SOL, NWAK, WASO). Analyses were performed separately by study design and population using a random-effects model (REML; Hartung-Knapp adjustment with IQWiG6 ad hoc correction); risk of bias was assessed with RoB 2 and ROBINS-I, and certainty of evidence with GRADE. Results For the PSQI, RCTs showed no statistically significant effect of HCL in subjects (6 studies, n=573; MD −0.30 [95% CI −0.92; 0.32]) or caregivers (3 studies, n=216; MD −1.39 [95% CI −3.66; 0.88]), despite a trend toward improvement in both groups. Non-randomized pre-post studies, encompassing a larger pooled sample, suggested a statistically significant improvement in sleep quality in both subjects (11 comparisons, n=672; MD −0.40 [95% CI −0.63; −0.17]) and caregivers (7 comparisons, n=372; MD −1.05 [95% CI −1.54; −0.56]). Conclusions Overall, the PSQI findings are directionally favorable to HCL, but the strength of inference differs by study design. The lack of a statistically significant effect in RCTs suggests that any benefit on perceived sleep quality is likely modest and still uncertain. By contrast, non-randomized pre-post studies show a clearer signal, though these results should be interpreted cautiously given their vulnerability to confounding, selection bias, and regression to the mean. The caregiver effect appears more pronounced than the subject effect, possibly reflecting a reduction in nocturnal diabetes-related burden, but this remains hypothesis-generating rather than definitive.
- Open Access
- 21 July 2026
- Published by Elsevier in SSRN Electronic Journal
Hybrid Closed-Loop Insulin Delivery and Sleep Health in Type 1 Diabetes: A Systematic Review and Meta-Analysis
Background: Sleep health has emerged as an important component of type 1 diabetes (T1D) management. Hybrid closed-loop (HCL) systems improve glycaemic outcomes and several psychosocial measures, but their effects on sleep remain uncertain. We conducted a systematic review and meta-analysis to evaluate the impact of commercially available HCL systems on subjective and objective sleep outcomes in people with T1D and their caregivers.Methods: We searched PubMed, Cochrane Library, Web of Science, ClinicalTrials.gov, and the WHO International Clinical Trials Registry Platform from July 15, 2015, to Jan 31, 2026, for randomised controlled trials (RCTs) and non-randomised studies of interventions (NRSIs) evaluating commercially available HCL systems. Comparators included multiple daily injections, conventional insulin pump therapy, sensor-augmented pump therapy, or alternative HCL systems. Primary subjective outcome was the Pittsburgh Sleep Quality Index (PSQI) global score; objective outcomes included actigraphy-derived total sleep time, sleep efficiency, wake after sleep onset, sleep onset latency, number of awakenings and time in bed. Random-effects meta-analyses were performed separately for RCTs and NRSIs studies, and certainty of evidence was assessed using GRADE.Findings: Twenty-four studies (ten RCTs and 14 NRSIs studies) met the inclusion criteria. In RCTs, HCL systems were associated with a non-significant improvement in PSQI global score in people with T1D (seven studies; n=629; mean difference [MD] −0·35, 95% CI −0·88 to 0·17) and caregivers (four studies; n=257; MD −0·86, −2·43 to 0·71). In contrast, NRSIs studies showed significant improvements in perceived sleep quality both in people with T1D (nine studies; n=651; MD −0·41, −0·65 to −0·17) and caregivers (six studies; n=292; MD −1·05, −1·54 to −0·56). Objective actigraphy-derived sleep measures showed no consistent changes across populations or study designs. Overall certainty of evidence ranged from moderate for RCT-based subjective outcomes to low or very low for most observational and objective outcomes.Interpretation: Commercially available HCL systems appear to improve perceived sleep quality in people with T1D and their caregivers, although this benefit was demonstrated primarily in NRSIs studies. Objective sleep parameters did not consistently improve, suggesting that HCL systems may preferentially reduce the perceived nocturnal burden of diabetes rather than modify measurable sleep architecture. Larger RCTs with predefined sleep outcomes and longer follow-up are needed to establish the clinical relevance and durability of these findings.
- 21 July 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessHybrid Closed-Loop Insulin Delivery and Sleep Health in Type 1 Diabetes: A Systematic Review and Meta-Analysis
Background: Sleep health has emerged as an important component of type 1 diabetes (T1D) management. Hybrid closed-loop (HCL) systems improve glycaemic outcomes and several psychosocial measures, but their effects on sleep remain uncertain. We conducted a systematic review and meta-analysis to evaluate the impact of commercially available HCL systems on subjective and objective sleep outcomes in people with T1D and their caregivers.Methods: We searched PubMed, Cochrane Library, Web of Science, ClinicalTrials.gov, and the WHO International Clinical Trials Registry Platform from July 15, 2015, to Jan 31, 2026, for randomised controlled trials (RCTs) and non-randomised studies of interventions (NRSIs) evaluating commercially available HCL systems. Comparators included multiple daily injections, conventional insulin pump therapy, sensor-augmented pump therapy, or alternative HCL systems. Primary subjective outcome was the Pittsburgh Sleep Quality Index (PSQI) global score; objective outcomes included actigraphy-derived total sleep time, sleep efficiency, wake after sleep onset, sleep onset latency, number of awakenings and time in bed. Random-effects meta-analyses were performed separately for RCTs and NRSIs studies, and certainty of evidence was assessed using GRADE.Findings: Twenty-four studies (ten RCTs and 14 NRSIs studies) met the inclusion criteria. In RCTs, HCL systems were associated with a non-significant improvement in PSQI global score in people with T1D (seven studies; n=629; mean difference [MD] −0·35, 95% CI −0·88 to 0·17) and caregivers (four studies; n=257; MD −0·86, −2·43 to 0·71). In contrast, NRSIs studies showed significant improvements in perceived sleep quality both in people with T1D (nine studies; n=651; MD −0·41, −0·65 to −0·17) and caregivers (six studies; n=292; MD −1·05, −1·54 to −0·56). Objective actigraphy-derived sleep measures showed no consistent changes across populations or study designs. Overall certainty of evidence ranged from moderate for RCT-based subjective outcomes to low or very low for most observational and objective outcomes.Interpretation: Commercially available HCL systems appear to improve perceived sleep quality in people with T1D and their caregivers, although this benefit was demonstrated primarily in NRSIs studies. Objective sleep parameters did not consistently improve, suggesting that HCL systems may preferentially reduce the perceived nocturnal burden of diabetes rather than modify measurable sleep architecture. Larger RCTs with predefined sleep outcomes and longer follow-up are needed to establish the clinical relevance and durability of these findings.
- Open Access
- 17 June 2026
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 16 (6) , 325
Special Issue—Diabetes Mellitus: Current Research and Future Perspectives, 2nd Edition
In 1922, Leonard Thompson, a 14-year-old patient with severe Type 1 Diabetes (T1D), became the first patient to receive an insulin injection
- 17 June 2026
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 16 (6) , 325
Open AccessSpecial Issue—Diabetes Mellitus: Current Research and Future Perspectives, 2nd Edition
In 1922, Leonard Thompson, a 14-year-old patient with severe Type 1 Diabetes (T1D), became the first patient to receive an insulin injection
- 21 April 2026
- Published by Elsevier in Pediatric Neurology
- Vol. 180, 75-81
Prenatal Diagnosis of Sepiapterin Reductase Deficiency: Lighting and Shadows of Early Treatment With L-DOPA/Carbidopa
- 21 April 2026
- Published by Elsevier in Pediatric Neurology
- Vol. 180, 75-81
Prenatal Diagnosis of Sepiapterin Reductase Deficiency: Lighting and Shadows of Early Treatment With L-DOPA/Carbidopa
- Open Access
- 24 February 2026
- Published by MDPI AG in Diabetology
- Vol. 7 (3) , 41
Recurrent Hypoglycemia as an Unusual Finding in Pediatric New-Onset Type 1 Diabetes: A Case Report and Review of the Literature
Introduction: Recurrent hypoglycemia occurring prior to the initiation of insulin therapy is an uncommon finding at the onset of pediatric type 1 diabetes mellitus (T1D). Aim: The aim of this study was to describe an unusual presentation of T1D onset characterized by recurrent hypoglycemia in a pediatric patient and to provide an updated review of the literature on hypoglycemic episodes occurring before insulin initiation in children with new-onset T1D. Case report: We present the case of a child who exhibited recurrent fasting hypoglycemia and postprandial hyperglycemia at the onset of T1D. Clinical findings also included persistently elevated glucagon levels (66–93 pmol/L; normal values [n.v.] 3–60); markedly elevated glycated hemoglobin (98 mmol/moL); low C-peptide levels (0.05 nmol/L); and a slight positivity for antibodies to glutamic acid decarboxylase (38.3 KUI/L; n.v. < 10). Review of the literature: A narrative review of the literature was conducted using the PubMed (MEDLINE) database to identify studies reporting hypoglycemia at the onset of T1D in pediatric patients prior to insulin initiation. The search included combinations of the terms hypoglycemia, new-onset, type 1 diabetes, child, and adolescent, with an exclusion of insulin-treated cases. We also explore potential pathogenetic mechanisms underlying this unusual presentation, including alpha-cell acute damage or dysregulation and loss of intra-islet paracrine signaling. Conclusions: Among individuals with T1D onset, episodes of recurrent hypoglycemia before the initiation of insulin therapy have been reported in a few studies. The presented case expands the clinical spectrum of early T1D and suggests that early alpha-cell dysfunction may contribute to atypical glycemic patterns during disease onset.
- 24 February 2026
- Published by MDPI AG in Diabetology
- Vol. 7 (3) , 41
Open AccessRecurrent Hypoglycemia as an Unusual Finding in Pediatric New-Onset Type 1 Diabetes: A Case Report and Review of the Literature
Introduction: Recurrent hypoglycemia occurring prior to the initiation of insulin therapy is an uncommon finding at the onset of pediatric type 1 diabetes mellitus (T1D). Aim: The aim of this study was to describe an unusual presentation of T1D onset characterized by recurrent hypoglycemia in a pediatric patient and to provide an updated review of the literature on hypoglycemic episodes occurring before insulin initiation in children with new-onset T1D. Case report: We present the case of a child who exhibited recurrent fasting hypoglycemia and postprandial hyperglycemia at the onset of T1D. Clinical findings also included persistently elevated glucagon levels (66–93 pmol/L; normal values [n.v.] 3–60); markedly elevated glycated hemoglobin (98 mmol/moL); low C-peptide levels (0.05 nmol/L); and a slight positivity for antibodies to glutamic acid decarboxylase (38.3 KUI/L; n.v. < 10). Review of the literature: A narrative review of the literature was conducted using the PubMed (MEDLINE) database to identify studies reporting hypoglycemia at the onset of T1D in pediatric patients prior to insulin initiation. The search included combinations of the terms hypoglycemia, new-onset, type 1 diabetes, child, and adolescent, with an exclusion of insulin-treated cases. We also explore potential pathogenetic mechanisms underlying this unusual presentation, including alpha-cell acute damage or dysregulation and loss of intra-islet paracrine signaling. Conclusions: Among individuals with T1D onset, episodes of recurrent hypoglycemia before the initiation of insulin therapy have been reported in a few studies. The presented case expands the clinical spectrum of early T1D and suggests that early alpha-cell dysfunction may contribute to atypical glycemic patterns during disease onset.
- 3 July 2025
- Published by S. Karger AG in Hormone Research in Paediatrics
- p. 1-9
An Unusual Liver and Kidney Involvement in Congenital Hyperinsulinism with HNF1A Mutation: A Case Report
Introduction: Hepatocyte nuclear factor-1α (HNF-1α) and hepatocyte nuclear factor-4α (HNF-4α) are transcription factors highly expressed in β-cells, hepatocytes, intestinal epithelial cells, and renal tubular cells. Variants in both HNF1A and HNF4A gene have been linked to maturity-onset diabetes of youth (MODY) and congenital hyperinsulinism (HI). To date, the association between HI, renal tubulopathy, and hepatopathy has been described only in patients with HNF-4α deficiency. HI due to HNF-1α deficiency has not been linked to extra-pancreatic features. Case Presentation: Our patient presented neonatal onset of HI and hepatomegaly, cholestasis, echographic features of liver steatosis, and renal tubulopathy (glycosuria, phosphaturia, aminoaciduria, uricosuria, proteinuria) from the first month of life. The molecular analysis revealed a heterozygous maternal variant c.4432G>A (p.Gly1478Ar) in the ABCC8 gene and a heterozygous maternal variant c.1859C>T (Thr620Ile) in HNF1A gene. We describe an 8-month follow-up and discuss possible pathogenetic mechanisms linking HNF1A-HI and features of extra-pancreatic involvement. Conclusion: Our case describes a likely association between HI due to HNF-1α deficiency with liver and kidney involvement. Further cases are needed to validate our hypothesis and to establish if a genotype-phenotype correlation exists in case of extra-pancreatic involvement, as for the known HNF4A mutation-specific phenotype.
- 3 July 2025
- Published by S. Karger AG in Hormone Research in Paediatrics
- p. 1-9
An Unusual Liver and Kidney Involvement in Congenital Hyperinsulinism with HNF1A Mutation: A Case Report
Introduction: Hepatocyte nuclear factor-1α (HNF-1α) and hepatocyte nuclear factor-4α (HNF-4α) are transcription factors highly expressed in β-cells, hepatocytes, intestinal epithelial cells, and renal tubular cells. Variants in both HNF1A and HNF4A gene have been linked to maturity-onset diabetes of youth (MODY) and congenital hyperinsulinism (HI). To date, the association between HI, renal tubulopathy, and hepatopathy has been described only in patients with HNF-4α deficiency. HI due to HNF-1α deficiency has not been linked to extra-pancreatic features. Case Presentation: Our patient presented neonatal onset of HI and hepatomegaly, cholestasis, echographic features of liver steatosis, and renal tubulopathy (glycosuria, phosphaturia, aminoaciduria, uricosuria, proteinuria) from the first month of life. The molecular analysis revealed a heterozygous maternal variant c.4432G>A (p.Gly1478Ar) in the ABCC8 gene and a heterozygous maternal variant c.1859C>T (Thr620Ile) in HNF1A gene. We describe an 8-month follow-up and discuss possible pathogenetic mechanisms linking HNF1A-HI and features of extra-pancreatic involvement. Conclusion: Our case describes a likely association between HI due to HNF-1α deficiency with liver and kidney involvement. Further cases are needed to validate our hypothesis and to establish if a genotype-phenotype correlation exists in case of extra-pancreatic involvement, as for the known HNF4A mutation-specific phenotype.
- Open Access
- 23 June 2025
- Published by MDPI AG in Metabolites
- Vol. 15 (7) , 427
Increased Lyso-Gb1 Levels in an Obese Splenectomized Gaucher Disease Type 1 Patient Treated with Eliglustat: Unacknowledged Poor Compliance or Underlying Factors
Eliglustat (Cerdelga®) is a potent and specific inhibitor of the enzyme glucosylceramide synthase and serves as a substrate reduction therapy for adult patients with Gaucher disease type 1 (GD1). It prevents the accumulation of several lipids, including glucosylsphingosine (also known as Lyso-Gb1). In addition to its role in diagnostics, Lyso-Gb1 has been proven to be a reliable biomarker for assessing disease severity and monitoring treatment efficacy. We present the case of an obese, splenectomized GD1 patient on long-term enzyme replacement therapy (ERT) who reported worsening fatigue and showed a progressive increase in Lyso-Gb1 levels after switching treatment from ERT to eliglustat. We provide a discussion of the potential clinical factors contributing to this outcome. As seen with ERT, Lyso-Gb1 levels during eliglustat treatment appear to respond earlier than other biochemical and clinical parameters. An increase in Lyso-Gb1 may signal early compromised clinical efficacy of the treatment. Data on biochemical and clinical outcomes in splenectomized or obese patients treated with eliglustat are limited, and the role of specific genotypes requires further clarification. The variability in responses to eliglustat highlights the complexity of GD and underscores the need for personalized approaches to treatment and monitoring.
- 23 June 2025
- Published by MDPI AG in Metabolites
- Vol. 15 (7) , 427
Open AccessIncreased Lyso-Gb1 Levels in an Obese Splenectomized Gaucher Disease Type 1 Patient Treated with Eliglustat: Unacknowledged Poor Compliance or Underlying Factors
Eliglustat (Cerdelga®) is a potent and specific inhibitor of the enzyme glucosylceramide synthase and serves as a substrate reduction therapy for adult patients with Gaucher disease type 1 (GD1). It prevents the accumulation of several lipids, including glucosylsphingosine (also known as Lyso-Gb1). In addition to its role in diagnostics, Lyso-Gb1 has been proven to be a reliable biomarker for assessing disease severity and monitoring treatment efficacy. We present the case of an obese, splenectomized GD1 patient on long-term enzyme replacement therapy (ERT) who reported worsening fatigue and showed a progressive increase in Lyso-Gb1 levels after switching treatment from ERT to eliglustat. We provide a discussion of the potential clinical factors contributing to this outcome. As seen with ERT, Lyso-Gb1 levels during eliglustat treatment appear to respond earlier than other biochemical and clinical parameters. An increase in Lyso-Gb1 may signal early compromised clinical efficacy of the treatment. Data on biochemical and clinical outcomes in splenectomized or obese patients treated with eliglustat are limited, and the role of specific genotypes requires further clarification. The variability in responses to eliglustat highlights the complexity of GD and underscores the need for personalized approaches to treatment and monitoring.
- 20 May 2025
- Published by Open Source Publications in Annals of Pediatrics and Neonatal Care
- Vol. 1 (1)
Early cardiac involvement in MELAS syndrome A pediatric case report
A 1 year old boy with a history of hypotonia and recurrent episodes of lactic acidosis during seasonal illnesses, was diagnosed with MELAS
- 20 May 2025
- Published by Open Source Publications in Annals of Pediatrics and Neonatal Care
- Vol. 1 (1)
Early cardiac involvement in MELAS syndrome A pediatric case report
A 1 year old boy with a history of hypotonia and recurrent episodes of lactic acidosis during seasonal illnesses, was diagnosed with MELAS
- Open Access
A Focus on the Role of Dietary Treatment in the Prevention of Retinal Dysfunction in Patients with Long-Chain 3-Hydroxyacyl-CoA Dehydrogenase Deficiency: A Systematic Review
Background: Long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency (LCHADD) is an inborn error affecting fatty acid β-oxidation (FAO). Differently than other FAO deficiencies, LCHADD patients may develop progressive retinopathy and peripheral neuropathy. The pathogenesis of retinopathy is not completely understood, and the role of dietary interventions in preventing the development of retinopathy remains uncertain. We examined the literature to assess the impact of the dietary management of LCHADD patients on retinopathy prevention. Methods: Our systematic search included studies published in the last 20 years according to PRISMA guidelines. The aims of the review were to analyze the correlation between retinopathy and the following: (1) age at first metabolic decompensation and/or at the start of the dietary treatment, (2) chronic dietary treatment, (3) emergency regimens, (4) other nutritional supplements. The protocol was registered in PROSPERO, and evidence was assessed using the GRADE system. Results: Seven full papers were identified according to search criteria, with only four including meaningful data. Early presentation of the disease, acute neonatal symptoms, and a suboptimal chronic treatment control were associated with more aggressive retinopathy and a poorer sight outcome. The number of metabolic decompensations and/or hospitalizations were also positively correlated with vision loss. Chronic fat modulation in the diet had less impact than emergency treatments. The role of other nutritional supplements was not well defined. Conclusions: Newborn screening may improve retinal outcomes. Nevertheless, early treatment adopting the current LCHADD therapeutic regimen can often only delay the onset of retinopathy. Clearly, our current treatment strategies are not adequate and retina-specific treatments are needed. The optimal composition of the diet, the role of fasting limitation, and the benefits of some nutritional supplements deserve further investigations.
Open AccessA Focus on the Role of Dietary Treatment in the Prevention of Retinal Dysfunction in Patients with Long-Chain 3-Hydroxyacyl-CoA Dehydrogenase Deficiency: A Systematic Review
Background: Long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency (LCHADD) is an inborn error affecting fatty acid β-oxidation (FAO). Differently than other FAO deficiencies, LCHADD patients may develop progressive retinopathy and peripheral neuropathy. The pathogenesis of retinopathy is not completely understood, and the role of dietary interventions in preventing the development of retinopathy remains uncertain. We examined the literature to assess the impact of the dietary management of LCHADD patients on retinopathy prevention. Methods: Our systematic search included studies published in the last 20 years according to PRISMA guidelines. The aims of the review were to analyze the correlation between retinopathy and the following: (1) age at first metabolic decompensation and/or at the start of the dietary treatment, (2) chronic dietary treatment, (3) emergency regimens, (4) other nutritional supplements. The protocol was registered in PROSPERO, and evidence was assessed using the GRADE system. Results: Seven full papers were identified according to search criteria, with only four including meaningful data. Early presentation of the disease, acute neonatal symptoms, and a suboptimal chronic treatment control were associated with more aggressive retinopathy and a poorer sight outcome. The number of metabolic decompensations and/or hospitalizations were also positively correlated with vision loss. Chronic fat modulation in the diet had less impact than emergency treatments. The role of other nutritional supplements was not well defined. Conclusions: Newborn screening may improve retinal outcomes. Nevertheless, early treatment adopting the current LCHADD therapeutic regimen can often only delay the onset of retinopathy. Clearly, our current treatment strategies are not adequate and retina-specific treatments are needed. The optimal composition of the diet, the role of fasting limitation, and the benefits of some nutritional supplements deserve further investigations.